<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02467868</url>
  </required_header>
  <id_info>
    <org_study_id>MYL-1401H-3001</org_study_id>
    <secondary_id>2014-002324-27</secondary_id>
    <nct_id>NCT02467868</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study With MYL-1401H and Neulasta</brief_title>
  <official_title>Multicenter, Double-Blind, Randomized, Comparative Efficacy and Safety Study of MYL-1401H and European Sourced Neulasta® in Stage II/III Breast Cancer Patients Receiving Neoadjuvant or Adjuvant Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mylan Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mylan GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mylan Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Multicenter, Double-Blind, Randomized, Comparative Efficacy and Safety Study of
      MYL-1401H and Neulasta (Pegfilgrastim) in Stage II/III Breast Cancer Patients Receiving
      Neoadjuvant or Adjuvant Chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After successful screening, eligible patients will be randomly allocated to one of the two
      study arms, either receiving MYL-1401H or Neulasta.

      Randomization is 2:1 to MYL-1401H or Neulasta, respectively.

      Subjects will receive first of six cycles of background therapy (Docetaxel, Doxorubicin,
      Cyclophosphamide [TAC]) on day 1. Treatment with study drug (either MYL-1401H or Neulasta) is
      scheduled on Day 2 of each cycle, at least 24 hours after chemotherapy administration.

      Duration of each cycle is 3 weeks.

      Follow-up visit is scheduled 24 weeks after the first administration of study drug.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Duration of Severe Neutropenia (DSN), defined as consecutive days with absolute neutrophil count (ANC) &lt; 0.5 × 109/L</measure>
    <time_frame>Cycle 1 of chemotherapy (approx 21 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of febrile neutropenia (FN)</measure>
    <time_frame>Week 24 (End of the study)</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence, nature, and severity of adverse events (AEs)</measure>
    <time_frame>Week 24</time_frame>
    <description>Rate of FN listed by cycles and across cycles</description>
  </other_outcome>
  <other_outcome>
    <measure>Presence of antibodies against MYL-1401H and Pegfilgrastim</measure>
    <time_frame>Week 24</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">193</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Chemotherapy-Induced Febrile Neutropenia</condition>
  <arm_group>
    <arm_group_label>MYL-1401H</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MYL-1401H</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neulasta</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neulasta</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MYL-1401H</intervention_name>
    <description>During each chemotherapy cycle MYL-1401H (6 mg) is administered s.c. 24 hours after chemotherapy.</description>
    <arm_group_label>MYL-1401H</arm_group_label>
    <other_name>Pegfilgrastim</other_name>
    <other_name>Recombinant human granulocyte colony-stimulating factor (G-CSF)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Neulasta</intervention_name>
    <description>During each chemotherapy cycle Neulasta (6 mg) is administered s.c. 24 hours after chemotherapy.</description>
    <arm_group_label>Neulasta</arm_group_label>
    <other_name>Pegfilgrastim</other_name>
    <other_name>Recombinant human granulocyte colony-stimulating factor (G-CSF)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed and dated written informed consent.

          -  Patients ≥18 years.

          -  Women of child-bearing potential must agree to use effective methods of birth control
             during the treatment period from the first dose of study drug until 6 months following
             the last dose of study drug.

          -  Newly diagnosed, pathologically confirmed breast cancer.

          -  Stage II or III breast cancer with adequate staging workup and adequate surgery if
             receiving adjuvant therapy.

          -  Patients planned/eligible to receive neoadjuvant or adjuvant treatment with
             (Docetaxel, Doxorubicin, Cyclophosphamide [TAC]) for their breast cancer.

          -  Cancer Chemotherapy and Radiotherapy naïve.

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1

          -  Absolute neutrophil count ≥ 1.5 × 109/L ; Platelet count ≥ 100 × 109/L ;

          -  Hemoglobin &gt; 10 g/dL without blood transfusions or cytokine support during the two
             weeks previous to the hemoglobin level.

          -  Adequate cardiac function (including left ventricular ejection fraction ≥ 50% as
             assessed by echocardiography) within 4 weeks prior to start of chemotherapy.

          -  Adequate renal function, i.e., creatinine &lt; 1.5 × upper limit of normal (ULN).

        Other protocol specific inclusion/exclusion criteria may apply

        Exclusion Criteria:

          -  Participation in a clinical trial in which they received an investigational drug
             within 28 days before randomization.

          -  Previous exposure to filgrastim, pegfilgrastim, lenograstim, lipegfilgrastim, or other
             filgrastim forms on the market or in clinical development.

          -  Received blood transfusions or erythroid growth factors within 2 weeks prior to first
             dose of chemotherapy.

          -  Known hypersensitivity to any drugs or excipients that patients will be receiving
             during the study.

          -  Known hypersensitivity to E. coli-derived products.

          -  Known fructose intolerance (related with sorbitol excipient).

          -  Underlying neuropathy of grade 2 or higher.

          -  Active infectious disease or any other medical condition which might put the patient
             at significant risk to tolerate 6 courses of TAC chemotherapy (e.g., recent myocardial
             infarction).

          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 2.5 × Upper limit
             of normal (ULN), ALT and/or AST &gt; 1.5 × ULN with alkaline phosphatase (ALP) &gt; 2.5 ×
             ULN; any bilirubin &gt; ULN.

          -  Treatment with systemically active antibiotics within 5 days before first dose of
             chemotherapy.

          -  Patients under treatment with lithium.

          -  Chronic use of oral corticosteroids.

          -  Splenomegaly of unknown origin by physical examination and/or computerized tomography
             scan or ultrasound and any condition which can cause splenomegaly, e.g., thalassemia,
             glandular fever, hemolytic anemias, and malaria.

          -  Myeloproliferative or myelodysplastic disorders, sickle cell disorders, and any
             illness or condition that in the opinion of the investigator may affect the safety of
             the patient or the evaluation of any study endpoint.

          -  Increase potential risk of Adult Respiratory Distress Syndrome.

          -  Pregnant or nursing women.

          -  Patients known to be seropositive for human immunodeficiency virus (HIV), or who have
             had an acquired immunodeficiency syndrome (AIDS) defining illness or a known
             immunodeficiency disorder.

          -  A known active abuse of drugs or alcohol should preclude patient participation and
             evaluation in the study.

          -  Any known psychiatric conditions.

          -  Any disease or physical condition that may not allow for the adequate performance of
             study assessments, such as lack of access to patient's domiciliary, and distance of
             patient's domiciliary from clinic site.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rasmus Rojkjaer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mylan GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mylan Investigational Site 3502</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site 3506</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site 3507</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site 3503</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site 3505</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational SIte 3501</name>
      <address>
        <city>Tarnovo</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site 3504</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site 9901</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site 9902</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site 9903</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site 9904</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site 9905</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site 9906</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site 9907</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational site 4905</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site 3604</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational SIte 3606</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site 3607</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site 3609</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site 3601</name>
      <address>
        <city>Gyula</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational SIte 3605</name>
      <address>
        <city>Nyiregyhaza</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site 3603</name>
      <address>
        <city>Szombathely</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site 3602</name>
      <address>
        <city>Zalaegerszeg</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational site 4802</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site 4805</name>
      <address>
        <city>Koscierzyna</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational SIte 4804</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational SIte 3804</name>
      <address>
        <city>Chernivtsi</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational site 3801</name>
      <address>
        <city>Dniepropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site 3805</name>
      <address>
        <city>Dniepropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site 3808</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site 3810</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigatational Site 3802</name>
      <address>
        <city>Lutsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational SIte 3807</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational SIte 3803</name>
      <address>
        <city>Odesa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site 3809</name>
      <address>
        <city>Sumy</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site 3806</name>
      <address>
        <city>Uzhgorod</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2015</study_first_submitted>
  <study_first_submitted_qc>June 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2015</study_first_posted>
  <last_update_submitted>March 15, 2016</last_update_submitted>
  <last_update_submitted_qc>March 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pegfilgrastim</keyword>
  <keyword>Granulocyte Colony Stimulating Factor (G-CSF)</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Neutropenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Febrile Neutropenia</mesh_term>
    <mesh_term>Chemotherapy-Induced Febrile Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

